News FDA experts lukewarm on AZ's anticoagulant antidote Andexxa AstraZeneca is facing some pushback as it tries to upgrade anticoagulant antidote drug Andexaa to full approval in the US
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
